BioPrev-C – development and validation of a contemporary prostate cancer risk calculator

BioPrev-C – development and validation of a contemporary prostate cancer risk calculator

ObjectivesTo develop a novel biopsy prostate cancer (PCa) prevention calculator (BioPrev-C) using data from a prospective cohort all undergoing mpMRI targeted and transperineal template saturation biopsy.Materials and methodsData of all men who underwent prostate biopsy in our academic tertiary care...

Full description

Bibliographic Details
Main Authors:	Thomas Hermanns, Marian S. Wettstein, Basil Kaufmann, Noémie Lautenbach, Ernest Kaufmann, Karim Saba, Florian A. Schmid, Andreas M. Hötker, Michael Müntener, Martin Umbehr, Cédric Poyet
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-02-01
Series:	Frontiers in Oncology
Subjects:	prostate cancer biopsy prostate-specific antigen nomograms decision aids
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1343999/full

Similar Items

Nomogram using transrectal ultrasound-derived information predicting the detection of high grade prostate cancer on initial biopsy
by: In Gab Jeong, et al.
Published: (2013-06-01)

Development and validation of a nomogram including lymphocyte-to-monocyte ratio for initial prostate biopsy: a double-center retrospective study
by: Zhong-Han Zhou, et al.
Published: (2021-01-01)

External validation of prostate health index-based nomogram for predicting prostate cancer at extended biopsy
by: Stojadinović Milorad M., et al.
Published: (2020-01-01)

MRI-Based Nomogram of Prostate Maximum Sectional Area and Its Zone Area for Prediction of Prostate Cancer
by: Shaoqin Jiang, et al.
Published: (2021-09-01)

Evaluation of Proclarix in the diagnostic work‐up of prostate cancer
by: Basil Kaufmann, et al.
Published: (2024-02-01)

Development and Internal Validation of Novel Nomograms Based on Benign Prostatic Obstruction-Related Parameters to Predict the Risk of Prostate Cancer at First Prostate Biopsy
by: Luigi Cormio, et al.
Published: (2018-10-01)

Interassay Variability and Clinical Implications of Five Different Prostate-specific Antigen Assays
by: Basil Kaufmann, et al.
Published: (2024-05-01)

Development and validation of a predictive model for diagnosing prostate cancer after transperineal prostate biopsy
by: Wenming Ren, et al.
Published: (2022-12-01)

Comparison of cancer detection rates by transrectal prostate biopsy for prostate cancer using two different nomograms based on patient’s age and prostate volume
by: Hori S, et al.
Published: (2019-03-01)

Developing a diagnostic model for predicting prostate cancer: a retrospective study based on Chinese multicenter clinical data
by: Chang-Ming Wang, et al.
Published: (2024-01-01)

Fusion Biopsy, not Cognitive, Is the New Gold Standard
by: Alessandro Marquis, et al.
Published: (2023-03-01)

Fusion Biopsy, not Cognitive, Is the New Gold Standard
by: Alessandro Marquis, et al.
Published: (2023-03-01)

Identification of Urine Biomarkers to Improve Eligibility for Prostate Biopsy and Detect High-Grade Prostate Cancer
by: Nagjie Alijaj, et al.
Published: (2022-02-01)

Development and validation of a predictive model based on clinical and MpMRI findings to reduce additional systematic prostate biopsy
by: Xueqing Cheng, et al.
Published: (2024-01-01)

Morbidity following transperineal prostate biopsy: Our experience in 8.500 men
by: Pietro Pepe, et al.
Published: (2022-06-01)

Acute prostatitis after prostate biopsy under ciprofloxacin prophylaxis with or without ornidazole and pre-biopsy enema: analysis of 3.479 prostate biopsy cases
by: Muhsin Balaban, et al.
Published: (2019-01-01)

COMPARATIVE EVALUATION OF CURRENT METHODS OF ANESTHESIA IN PERFORMANCE OF TRANSRECTAL PROSTATE BIOPSY
by: M. E. Topuzov, et al.
Published: (2015-10-01)

Anterior prostate biopsy at initial and repeat evaluation: is it useful to detect significant prostate cancer?
by: Pietro Pepe, et al.
Published: (2015-10-01)

Nonspecific Presentation of a Multiloculated Prostatic Abscess After Transurethral Prostatic Biopsy for Elevated Prostate-specific Antigen Level
by: Nilay M. Gandhi, et al.
Published: (2014-11-01)

Development and internal validation of a prediction model of prostate cancer on initial transperineal template-guided prostate biopsy
by: Yuliang Chen, et al.
Published: (2021-04-01)

Rebiopsy rate after transperineal or transrectal prostate biopsy
by: Jose L. Marenco Jimenez, et al.
Published: (2021-06-01)

Routine systematic prostate biopsies not replaced by magnetic resonance imaging-targeted biopsy
by: David Gómez-Ortiz, et al.
Published: (2022-10-01)

Repeated biopsy in the detection of prostate cancer: When and how many cores
by: Vincenzo Scattoni, et al.
Published: (2014-12-01)

Prostatic Inflammation in Prostate Cancer: Protective Effect or Risk Factor?
by: Alessandro Tafuri, et al.
Published: (2021-06-01)

Inflammation and Prostate Cancer: Pathological Analysis from Pros-IT CNR 2
by: Francesco Sessa, et al.
Published: (2023-01-01)

Development and validation of a multi-parameter nomogram for predicting prostate cancer: a retrospective analysis from Handan Central Hospital in China
by: Libin Nan, et al.
Published: (2022-03-01)

HistoScanning<sup>TM</sup> vs. standard multifocal biopsy for prostate cancer diagnosis: a comparison of diagnostic methods
by: S. V. Kotov, et al.
Published: (2023-12-01)

Indications for a second prostate biopsy in patients suspected with prostate cancer after an initial negative prostate biopsy
by: Kwang Suk Lee, et al.
Published: (2017-03-01)

A retrospective comparison between transrectal and transperineal prostate biopsy in the detection of prostate cancer
by: Carmelo Agostino Di Franco, et al.
Published: (2017-03-01)

A review of transrectal ultrasound guided prostate biopsies: Is there still a role for finger guided prostate biopsies?
by: K.S. Jehle, et al.
Published: (2015-03-01)

Prostate chronic inflammation type IV and prostate cancer risk in patients undergoing first biopsy set: Results of a large cohort study
by: Antonio Benito Porcaro, et al.
Published: (2015-10-01)

Long-term outcomes of nonpalpable prostate cancer (T1c) patients treated with radical prostatectomy
by: Yoshiyasu Amiya, et al.
Published: (2015-03-01)

Percentage of free prostate-specific antigen (PSA) is a useful method in deciding to perform prostate biopsy with higher core numbers in patients with low PSA cut-off values
by: Hasan Yilmaz, et al.
Published: (2015-06-01)

Is It Effective to Perform Two More Prostate Biopsies According to Prostate-Specific Antigen Level and Prostate Volume in Detecting Prostate Cancer? Prospective Study of 10-Core and 12-Core Prostate Biopsy
by: Byung Il Yoon, et al.
Published: (2012-05-01)

The Severity of Pain in Prostate Biopsy Depends on the Biopsy Sector
by: Grzegorz Rempega, et al.
Published: (2023-02-01)

Continued administration of antithrombotic agents during transperineal prostate biopsy
by: Toko Asano, et al.
Published: (2015-02-01)

Short-term prophylaxis with ciprofloxacin in extended 16-core prostate biopsy
by: Renato Caretta Chambó, et al.
Published: (2015-02-01)

Transperineal ultrasound-guided prostate biopsy: what the radiologist needs to know
by: Jack Power, et al.
Published: (2022-04-01)

Predicting Significance of Blood Parameters in Diagnosis of Prostate Carcinoma in a Tertiary Centre in Udaipur, Rajasthan
by: Gulshan Kumar Mukhiya, et al.
Published: (2021-04-01)

Chronic inflammation of the prostate type IV with respect to risk of prostate cancer
by: Antonio B. Porcaro, et al.
Published: (2014-09-01)